Impact of Clopidogrel on Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: a National Retrospective Cohort Study.
Aisling R Caffrey, Haley J Appaneal, Kerry L LaPlante...
https://pubmed.ncbi.nlm.nih.gov/35416712/Actively Recruiting
Led by Todd C. Lee MD MPH FIDSA · Updated on 2026-09-24
300
Participants Needed
3
Research Sites
N/A
Total Duration
Researchers are evaluating the effects of switching from aspirin to clopidogrel in patients with Staphylococcus aureus bloodstream infections who are already taking aspirin for secondary prevention of cardiovascular events. This open-label randomized controlled trial aims to determine if clopidogrel, which may have activity against S. aureus, can improve outcomes compared to continuing aspirin. This study is a sub-study of the Staphylococcus aureus Network Adaptive Platform SNAP trial and may support a larger Phase 3 trial if the results are positive. Participants will be randomly assigned to one of two groups those who stop aspirin and start clopidogrel without a loading dose, and those who continue their existing aspirin therapy. This comparison will help assess the potential benefits of clopidogrel in managing S. aureus bacteremia while maintaining cardiovascular protection. The study will follow participants up to 90 days after enrollment in the SNAP trial. During the trial, participants will be monitored for outcomes including the Desirability of Outcome Ranking DOOR at day 90, clinical failure, serious adverse events or adverse events leading to discontinuation, mortality, infectious complications, and various cardiovascular and bleeding events. Safety and treatment effects will be carefully assessed throughout the study period. The total duration from enrollment to primary outcome measurement is 90 days.
CONDITIONS
Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
F
Fatima Amari
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Todd C. Lee MD MPH FIDSA
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 90 days
Participants are randomly assigned to either stop aspirin and start clopidogrel or continue their existing aspirin therapy.
Visits as scheduled within the SNAP trial
Duration - Up to 90 days post enrollment
Participants are monitored for outcomes including health status, adverse events, and cardiovascular complications through day 90 post enrollment.
Regular assessments during follow-up
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Aisling R Caffrey, Haley J Appaneal, Kerry L LaPlante...
https://pubmed.ncbi.nlm.nih.gov/35416712/Steven Y C Tong, Jocelyn Mora, Asha C Bowen...
https://pubmed.ncbi.nlm.nih.gov/35717634/Chris A Gentry, Riley J Williams, Charles M Whitman...
https://pubmed.ncbi.nlm.nih.gov/36736927/Todd C. Lee MD MPH FIDSA
Lead Sponsor